Javier Serradilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Javier Serradilla has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Alba Bueno
Transplant Group La Paz University Hospital Health Research Institute (IdiPAZ) Madrid Spain
10 shared publicationsAlida Alcolea
La Paz University Hospital, Pediatric Gastroenterology Intestinal Rehabilitation Unit, Madrid, SPAIN
6 shared publicationsEsther Ramos
La Paz University Hospital, Pediatric Gastroenterology and Intestinal Rehabilitation Unit, Madrid, Spain
6 shared publications- Francisco Hernández
Pediatric Surgery Department, Hospital Universitario La Paz, 28046 Madrid, Spain
5 shared publications - Pablo Stringa
Congenital Malformations and Transplantation Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; Institute for Immunological and Pathophysiological Studies (IIFP), School of Exact Sciences, National University of La Plata, National Council of Scientific and Technical Research (CONICET), La Plata, Argentina; Organ Transplant Laboratory, School of Medicine, National University of La Plata, La Plata, Argentina
5 shared publications - Ane Miren Andrés
Congenital Malformations and Transplantation Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain; Department of Pediatric Surgery, La Paz University Hospital (Hospital Universitario La Paz, HULP), Madrid, Spain
4 shared publications
Latest Publications
- 26 June 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 325, 496-505
Effects of Cold Preservation on Intestinal Grafts from Donation after Circulatory Death and Brain Death Donors in an Experimental Model
- 26 June 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 325, 496-505
Effects of Cold Preservation on Intestinal Grafts from Donation after Circulatory Death and Brain Death Donors in an Experimental Model
- 11 December 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 317, 189-198
Learning Curve for Rat Intestinal Transplantation: Milestones From a Single Surgeon's Perspective
- 11 December 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 317, 189-198
Learning Curve for Rat Intestinal Transplantation: Milestones From a Single Surgeon's Perspective
- Open Access
- 27 June 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (7S) , 37
63: DCD in intestinal transplantation: the path to prove its validity in both experimental and clinical models
- 27 June 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (7S) , 37
Open Access63: DCD in intestinal transplantation: the path to prove its validity in both experimental and clinical models
- Open Access
- 5 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (4) , 577-581
First case report of multivisceral transplant from a deceased cardiac death donor
- 5 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (4) , 577-581
Open AccessFirst case report of multivisceral transplant from a deceased cardiac death donor
- 26 June 2021
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (10) , 1895-1907
Delayed introduction of sirolimus in paediatric intestinal transplant recipients: indications and long‐term benefits
Aim To review our experience using sirolimus in a single center pediatric intestinal transplantation cohort. Patient/Methods Intestinal transplant patients with more than 3 months follow-up were divided in two groups according to their immunosuppression regimen: tacrolimus, (TAC group, n=45 grafts) or sirolimus (SRL group, n=38 grafts), which included those partially or completely converted from tacrolimus to sirolimus. The indications to switch were tacrolimus side-effects and immunological complications. Survival and complications were retrospectively analyzed comparing both groups. Results SRL was introduced 9 months (0 months-16.9 years) after transplant. The main cause for conversion was worsening renal function (45%), followed by hemolytic anemia (21%) and graft-versus-host-disease (16%). Both groups showed a similar overall patient/graft survival (p=0.76/0.08) and occurrence of rejection (24%/17%, p=0.36). Immunological complications did not recur after conversion. Renal function significantly improved in most SRL patients. After a median follow-up of 65.17 months, 28/46 survivors were on SRL, 26 with monotherapy, with good graft function. Conclusions Over one-third of our patients eventually required SRL conversion that allowed to improve their kidney function and immunological events, without entailing additional complications or survival impairment. Further trials are warranted to clarify the potential improvement of the standard tacrolimus maintenance by sirolimus conversion or addition.
- 26 June 2021
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (10) , 1895-1907
Delayed introduction of sirolimus in paediatric intestinal transplant recipients: indications and long‐term benefits
Aim To review our experience using sirolimus in a single center pediatric intestinal transplantation cohort. Patient/Methods Intestinal transplant patients with more than 3 months follow-up were divided in two groups according to their immunosuppression regimen: tacrolimus, (TAC group, n=45 grafts) or sirolimus (SRL group, n=38 grafts), which included those partially or completely converted from tacrolimus to sirolimus. The indications to switch were tacrolimus side-effects and immunological complications. Survival and complications were retrospectively analyzed comparing both groups. Results SRL was introduced 9 months (0 months-16.9 years) after transplant. The main cause for conversion was worsening renal function (45%), followed by hemolytic anemia (21%) and graft-versus-host-disease (16%). Both groups showed a similar overall patient/graft survival (p=0.76/0.08) and occurrence of rejection (24%/17%, p=0.36). Immunological complications did not recur after conversion. Renal function significantly improved in most SRL patients. After a median follow-up of 65.17 months, 28/46 survivors were on SRL, 26 with monotherapy, with good graft function. Conclusions Over one-third of our patients eventually required SRL conversion that allowed to improve their kidney function and immunological events, without entailing additional complications or survival impairment. Further trials are warranted to clarify the potential improvement of the standard tacrolimus maintenance by sirolimus conversion or addition.
- Open Access
- 2 August 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (1) , e13430
Novel coronavirus (SARS‐CoV‐2) infection in a patient with multivisceral transplant
- 2 August 2020
- Published by Wiley in Transplant Infectious Disease
- Vol. 23 (1) , e13430
Open AccessNovel coronavirus (SARS‐CoV‐2) infection in a patient with multivisceral transplant
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S9
250.7: Impact of donor selection on early graft loss in Intestinal Transplantation.
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S9
250.7: Impact of donor selection on early graft loss in Intestinal Transplantation.
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S135
P3.54: Grafted colon in intestinal transplantation: does it make a difference in the outcome of the patients?
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S135
P3.54: Grafted colon in intestinal transplantation: does it make a difference in the outcome of the patients?
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S133-S134
P3.52: THE USE OF ALEMTUZUMAB AS IMMUNOSUPPRESSIVE INDUCTION IN INTESTINAL TRANSPLANTATION AMONG PEDIATRIC POPULATION
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S133-S134
P3.52: THE USE OF ALEMTUZUMAB AS IMMUNOSUPPRESSIVE INDUCTION IN INTESTINAL TRANSPLANTATION AMONG PEDIATRIC POPULATION
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S49
P3A.10: Accumulated experience with Sirolimus in Pediatric Intestinal Transplantation
- 1 July 2019
- Published by Wolters Kluwer Health in Transplantation
- Vol. 103 (7S2) , S49
P3A.10: Accumulated experience with Sirolimus in Pediatric Intestinal Transplantation